GoodRx Holdings (GDRX) Liabilities and Shareholders Equity (2019 - 2026)

GoodRx Holdings' Liabilities and Shareholders Equity history runs 8 years deep, the most recent figure standing at $2.0 billion for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 56.05% year-over-year to $2.0 billion; the TTM figure through Mar 2026 stood at $6.1 billion (up 10.08% YoY), while the FY2025 annual figure was $1.4 billion, up 1.15% from the prior year.
• Liabilities and Shareholders Equity came in at $2.0 billion for Q1 2026 at GoodRx Holdings, up from $1.4 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $2.0 billion in Q1 2026 to a low of $1.3 billion in Q1 2025.
• A 5-year average of $1.5 billion and a median of $1.5 billion in 2022 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity retreated 20.68% in 2024 and jumped 56.05% in 2026, its largest moves.
• GoodRx Holdings' Liabilities and Shareholders Equity stood at $1.6 billion in 2022, then decreased by 0.99% to $1.6 billion in 2023, then decreased by 12.63% to $1.4 billion in 2024, then gained by 1.15% to $1.4 billion in 2025, then soared by 43.96% to $2.0 billion in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $2.0 billion, $1.4 billion, and $1.3 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison